Clinical Trial Update: Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder [Phase 2]

View source ↗

Summary

An open-label Phase 2 trial of Rapastinel (formerly GLYX-13) in obsessive-compulsive disorder has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obsessive-compulsive Disorder

Drugs mentioned

• Rapastinel (Rapastinel)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Obsessive-Compulsive Disorder (OCD) | Phase 2 | Status: COMPLETED | Results posted: 2017-05-10